Vardenafil (Levitra/Staxyn) and Testosterone Interaction

Why Clinicians Prescribe Both Drugs Together

Erectile dysfunction (ED) and low testosterone frequently coexist in the same patient. Approximately 30 percent of men presenting with ED have concurrent testosterone deficiency, defined as a total testosterone below 300 ng/dL according to the American Urological Association (AUA) guidelines. For these patients, a PDE5 inhibitor like vardenafil addresses the immediate vascular component of ED while testosterone replacement therapy (TRT) corrects the underlying hormonal deficit.

A 2004 randomized trial by Aversa et al. (N=60) demonstrated that men with both hypogonadism and ED who received testosterone gel plus a PDE5 inhibitor had significantly better erectile function scores than those receiving either agent alone [1]. The rationale is straightforward: testosterone upregulates nitric oxide synthase (NOS) expression in cavernosal tissue, increasing the substrate on which PDE5 inhibitors act. Without adequate testosterone, the NO-cGMP signaling pathway that vardenafil amplifies may be insufficient to produce a clinical erection [2].

This is not a fringe prescribing pattern. The Endocrine Society's 2018 clinical practice guideline recommends considering combination therapy when PDE5 inhibitors alone fail in hypogonadal men.

Pharmacokinetic Profile: No Metabolic Conflict

Vardenafil is primarily metabolized by CYP3A4, with minor contributions from CYP3A5 and CYP2C9, as described in the FDA-approved prescribing information for Levitra. Its major active metabolite, M1 (desethyl-vardenafil), accounts for about 7 percent of total pharmacologic activity.

Testosterone, whether administered as cypionate, enanthate, or transdermal gel, does not undergo CYP3A4-mediated metabolism in a clinically meaningful way. Testosterone is primarily reduced by 5-alpha reductase and 3-alpha hydroxysteroid dehydrogenase, then conjugated via glucuronidation and sulfation [3]. It does not inhibit or induce CYP3A4.

This means the two drugs do not compete for the same metabolic pathway. Co-administration will not raise vardenafil plasma levels or accelerate testosterone clearance. No dose reduction of either agent is needed on pharmacokinetic grounds alone. The FDA labels for both Levitra and testosterone cypionate do not list a drug-drug interaction between these two medications.

P-glycoprotein (P-gp) transport is also a non-issue. While vardenafil is a substrate of P-gp, testosterone is not a known P-gp inhibitor or inducer [4].

Pharmacodynamic Overlap: Where the Real Monitoring Lives

The interaction between vardenafil and testosterone is pharmacodynamic, not pharmacokinetic. Both drugs influence cardiovascular parameters, and their combined effects require clinical attention even though no formal contraindication exists.

Hematocrit and polycythemia. Testosterone stimulates erythropoiesis through direct effects on erythroid progenitor cells and suppression of hepcidin. In the Testosterone Trials (TTrials), mean hematocrit increased by 2.6 percentage points over 12 months in men receiving testosterone gel (N=394 in the sexual function substudy). Hematocrit above 54 percent is the standard threshold for dose reduction or temporary cessation per Endocrine Society guidelines [5]. Vardenafil does not independently affect hematocrit, but an elevated red cell mass increases blood viscosity and thrombotic risk. PDE5 inhibitors produce modest vasodilation, which could theoretically mask early symptoms of hyperviscosity such as headache and flushing. Monitoring CBC every 3 to 6 months is the standard of care.

Blood pressure. Vardenafil lowers systolic blood pressure by approximately 5 to 10 mmHg and diastolic by 4 to 5 mmHg at peak plasma concentrations [6]. Testosterone may raise blood pressure modestly: a 2020 meta-analysis by Corona et al. Found a mean systolic increase of 3.1 mmHg with TRT [7]. These opposing effects tend to partially offset each other, but individual responses vary. Patients on antihypertensives should have blood pressure rechecked after starting the combination.

Lipid metabolism. Testosterone replacement typically reduces HDL cholesterol by 5 to 15 percent, with variable effects on LDL and triglycerides depending on the formulation and dose [8]. Vardenafil is lipid-neutral. The clinical significance of TRT-related HDL reduction remains debated, but the TRAVERSE trial (N=5,246) found no increase in major adverse cardiovascular events (MACE) with testosterone gel over a mean follow-up of 33 months, offering some reassurance [9].

Monitoring Protocol for the Combination

A structured monitoring schedule reduces risk and catches problems early. The following protocol aligns with Endocrine Society and AUA recommendations adapted for dual-therapy patients.

Baseline (before starting combination): Total testosterone, free testosterone, CBC with hematocrit, comprehensive metabolic panel, fasting lipid panel, PSA (men over 40), blood pressure, and a validated ED questionnaire such as the IIEF-5.

Week 4 to 6: Follow-up blood pressure check. Assess subjective response to combination. If using injectable testosterone, time the blood draw at trough (immediately before next injection) to capture the lowest hematocrit reading.

Month 3: Repeat CBC with hematocrit, total testosterone (trough), and lipid panel. If hematocrit exceeds 54 percent, reduce testosterone dose or frequency and recheck in 4 weeks. If lipids worsen significantly, consider statin therapy or switch testosterone formulations.

Month 6: Repeat all baseline labs. Reassess ED response and adjust vardenafil dose (5 mg, 10 mg, or 20 mg) as needed. For patients on Staxyn (vardenafil ODT 10 mg), note that this formulation is not dose-adjustable and not bioequivalent to Levitra film-coated tablets.

Every 6 to 12 months thereafter: CBC, testosterone level, lipid panel, PSA. Annual digital rectal exam per AUA guidance for men on TRT [10].

Dose Adjustment Considerations

Vardenafil does not require dose adjustment when added to stable TRT. Standard dosing is 10 mg taken approximately 60 minutes before sexual activity, with titration to 5 mg or 20 mg based on efficacy and tolerability. The maximum frequency is once daily.

Testosterone dose selection depends on the formulation and the target trough level (typically 400 to 700 ng/dL for most guidelines). Common starting regimens include testosterone cypionate 100 to 200 mg intramuscularly every 2 weeks, testosterone enanthate on a similar schedule, or transdermal testosterone gel 1% at 50 mg daily.

One scenario that does require dose caution: patients taking testosterone alongside strong CYP3A4 inhibitors such as ketoconazole, ritonavir, or itraconazole. These drugs raise vardenafil plasma levels by 10-fold or more according to the Levitra label. The vardenafil dose should not exceed 5 mg per 24 hours when a strong CYP3A4 inhibitor is also prescribed [6]. Testosterone is not the culprit here, but clinicians managing complex medication regimens should audit the full drug list.

Alpha-blocker co-administration also warrants attention. If a patient on vardenafil and testosterone also takes tamsulosin or another alpha-blocker for benign prostatic hyperplasia, vardenafil should be initiated at 5 mg and separated from the alpha-blocker dose by at least 6 hours.

Cardiovascular Safety Data

The cardiovascular safety of this combination draws on data for each drug individually, since no large randomized trial has studied the pair in isolation.

For testosterone, the TRAVERSE trial established non-inferiority to placebo for MACE in men aged 45 to 80 with hypogonadism and pre-existing or high risk of cardiovascular disease (HR 0.96 to 95% CI 0.78 to 1.17) [9]. This was the first adequately powered cardiovascular outcomes trial for TRT and largely resolved the safety concerns raised by earlier observational studies.

For vardenafil, post-marketing surveillance and pooled clinical trial data covering over 8,000 patients showed no signal of increased myocardial infarction or stroke risk at standard doses [11]. The absolute contraindication with organic nitrates remains in effect because PDE5 inhibition potentiates nitrate-mediated vasodilation, producing potentially fatal hypotension.

Dr. Abraham Morgentaler, Associate Clinical Professor of Urology at Harvard Medical School, has stated: "The combination of testosterone therapy and PDE5 inhibitors is one of the most effective treatment strategies for men with hypogonadism and erectile dysfunction. The two agents work through complementary mechanisms" [12].

The 2018 AUA/Sexual Medicine Society of North America guideline on ED notes: "In men with ED and documented low testosterone, a trial of testosterone therapy alone or in combination with a PDE5 inhibitor is a reasonable treatment approach" [13].

Special Populations

Men over 65. Vardenafil clearance is reduced by approximately 52 percent in men aged 65 and older compared with younger men, per the FDA label. Starting at 5 mg is recommended. Testosterone doses in this age group should target the lower end of the reference range, and hematocrit monitoring becomes especially important given age-related baseline elevations.

Hepatic impairment. In patients with moderate hepatic impairment (Child-Pugh B), vardenafil starting dose should be 5 mg with a maximum of 10 mg. Testosterone metabolism is also hepatic, and liver disease alters sex hormone-binding globulin (SHBG) levels, complicating interpretation of total testosterone values. Free testosterone assays are preferred in this population [5].

Renal impairment. No dose adjustment is needed for vardenafil in mild to moderate renal impairment. Severe renal impairment (CrCl <30 mL/min) has not been studied. Testosterone dosing is generally unchanged, though fluid retention may be exacerbated.

Patients with sleep apnea. Testosterone may worsen obstructive sleep apnea (OSA). Vardenafil has no known effect on OSA. Patients with untreated severe OSA should have the condition addressed before initiating TRT, per Endocrine Society recommendations [5].

Patient Counseling Points

Patients prescribed both vardenafil and testosterone should understand several practical points. Take vardenafil on an as-needed basis, not daily, and avoid high-fat meals before dosing since fat reduces peak absorption by approximately 18 to 50 percent. Do not take vardenafil with grapefruit juice, which inhibits CYP3A4 and raises drug levels.

Report any of the following promptly: sustained headache, visual disturbances, priapism (erection lasting more than 4 hours), chest pain, or symptoms of polycythemia such as facial plethora, blurred vision, or tingling in the extremities.

Testosterone benefits on erectile function may take 3 to 6 months to appear fully. An early lack of improvement does not mean the combination has failed. Continue vardenafil as needed during this ramp-up period.

Alcohol in moderation (two or fewer standard drinks) is generally acceptable with vardenafil, but excessive alcohol amplifies the hypotensive effect.

Both drugs should be obtained through a licensed pharmacy. Counterfeit vardenafil and testosterone products are well-documented in online gray markets and may contain incorrect doses or contaminants.

When the Combination May Not Be Appropriate

Not every patient with ED and low testosterone is a candidate for dual therapy. Absolute contraindications to vardenafil include concurrent nitrate use, recent stroke or MI within 6 months, unstable angina, and hereditary retinal disorders such as retinitis pigmentosa. Absolute contraindications to testosterone include metastatic prostate cancer, unevaluated PSA elevation, hematocrit above 54 percent at baseline, untreated severe OSA, uncontrolled heart failure (NYHA class IV), and desire for current fertility (testosterone suppresses spermatogenesis) [5].

If a patient has contraindications to one agent, the other can often be used alone. Men with hypogonadism who cannot take PDE5 inhibitors may benefit from intracavernosal injection therapy or vacuum erection devices alongside TRT. Men with normal testosterone who do not respond to vardenafil should be evaluated for vascular or psychogenic causes before adding unnecessary hormonal therapy.

Baseline hematocrit above 50 percent is a relative contraindication to testosterone, requiring careful risk-benefit discussion and more frequent monitoring if therapy proceeds. A 2019 retrospective cohort study (N=3,422) found that the rate of venous thromboembolism in TRT users with hematocrit persistently above 52 percent was 5.3 per 1,000 person-years compared with 1.9 per 1,000 person-years in those below 50 percent [14].